Evidence map›Paper›PMID 32351502›Full record

ArticleFrontiers in immunology2020

Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party.

Olaf Penack, Christophe Peczynski, Steffie van der Werf, Jürgen Finke, Arnold Ganser, Helene Schoemans, Jiri Pavlu, Riitta Niittyvuopio, Wilfried Schroyens, Leylagül Kaynar and 14 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 11 countries.

Olaf PenackDepartment of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Christophe PeczynskiEBMT Statistical Unit, Paris, France.
Steffie van der WerfEBMT Data Office, Leiden, Netherlands.
Jürgen FinkeDepartment of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Arnold GanserHannover Medical School, Hanover, Germany.
Helene SchoemansDepartment of Hematology, University Hospital Leuven, KU Leuven, Leuven, Belgium.
Jiri PavluImperial College London, London, United Kingdom.
Riitta NiittyvuopioHUCH Comprehensive Cancer Center, Helsinki, Finland.
Wilfried SchroyensAntwerp University Hospital, Antwerp, Belgium.
Leylagül KaynarMedical Faculty, Erciyes University, Kayseri, Turkey.
Igor W BlauDepartment of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Walter J F M van der VeldenMedical Centre, Radboud University, Nijmegen, Netherlands.
Jorge SierraHospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Agostino CortelezziFondazione IRCCS Ca' Granda, University of Milan, Milan, Italy.
Gerald WulfDepartment of Hematology and Medical Oncology, Universitätsklinikum Göttingen, Göttingen, Germany.
Pascal TurlureCHRU Limoges, Limoges, France.
Montserrat RoviraHospital Clinic, Barcelona, Spain.
Zubeydenur OzkurtFaculty of Medicine, Gazi University, Ankara, Turkey.
Maria J Pascual-CasconHospital Regional de Málaga, Málaga, Spain.
Maria C MoreiraInstituto National do Cancer, Rio de Janeiro, Brazil.
Johannes ClausenElisabethinen Hospital, Linz, Austria.
Hildegard GreinixDepartment of Hematology and Oncology, Medical University of Graz, Graz, Austria.
Rafael F DuarteHospital Universitario Puerta de Hierro, Madrid, Spain.
Grzegorz W BasakDepartment of Hematology and Oncology, Medical University of Warsaw, Warsaw, Poland.
Charité - Universitätsmedizin Berlin · DEAntwerp University Hospital · BECentre Hospitalier Universitaire de Limoges · FRErciyes University · TREuropean Society for Blood and Marrow Transplantation · FREuropean Society for Blood and Marrow Transplantation · NLGazi University · TRHospital Clínic de Barcelona · ESHospital de Sant Pau · ESHospital Regional Universitario de Málaga · ESHospital Universitario Puerta de Hierro Majadahonda · ESImperial College London · GBInstituto Nacional do Câncer · BRKrankenhaus der Elisabethinen · ATKU Leuven · BEMedical University of Graz · ATMedical University of Warsaw · PLMedizinische Hochschule Hannover · DERadboud University Medical Center · NLUniversitätsmedizin Göttingen · DE

Funding

Department of Health
6 · The paper itself

Abstract

Elevated serum ferritin levels occur due to iron overload or during inflammation and macrophage activation. A correlation of high serum ferritin levels with increased mortality after alloSCT has been suggested by several retrospective analyses as well as by two smaller prospective studies. This prospective multicentric study aimed to study the association of ferritin serum levels before start of conditioning with alloSCT outcome. Patients with acute leukemia, lymphoma or MDS receiving a matched sibling alloSCT for the first time were considered for inclusion, regardless of conditioning. A comparison of outcomes between patients with high and low ferritin level was performed using univariate analysis and multivariate analysis using cause-specific Cox model. Twenty centers reported data on 298 alloSCT recipients. The ferritin cut off point was determined at 1500 μg/l (median of measured ferritin levels). In alloSCT recipients with ferritin levels above cut off measured before the start of conditioning, overall survival (HR = 2.5, CI = 1.5-4.1,

Indexed as

AdolescentAdultAgedBiomarkers, TumorFemaleFerritinsGraft vs Host DiseaseHematologic NeoplasmsHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPostoperative ComplicationsProspective StudiesTransplantation ConditioningTransplantation, HomologousBiomarkers, TumorFerritinsbiomarkerferritinimmunologyiron metabolismstem celltransplantation

Identifiers

PMID32351502
PMCPMC7174614
OpenAlexW3016666162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.